Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Pérez-Civantos, D.V. (D. V.) | - |
dc.creator | Robles-Marcos, M. (M.) | - |
dc.creator | Azanza, J.R. (José Ramón) | - |
dc.creator | Pazos-Pacheco, C. (C.) | - |
dc.creator | García-Montoto-Pérez, F. (F.) | - |
dc.creator | Gómez-Coronado, V. (V.) | - |
dc.date.accessioned | 2022-06-09T11:16:49Z | - |
dc.date.available | 2022-06-09T11:16:49Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Pérez-Civantos, D.V. (D. V.); Robles-Marcos, M. (M.); Azanza, J.R. (José Ramón); et al. "Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis". International Journal of Infectious Diseases. 86, 2019, 142 - 146 | es |
dc.identifier.issn | 1201-9712 | - |
dc.identifier.uri | https://hdl.handle.net/10171/63624 | - |
dc.description.abstract | Objective: To describe the pharmacokinetic (PK) profile of anidulafungin and to evaluate its concentration in the peritoneal fluid (PF) of patients suspected of suffering from peritoneal infection undergoing abdominal surgery, in order to ensure that therapeutic levels are achieved within the peritoneal cavity. Methods: A descriptive, open, prospective, observational, multicentre and non-interventional study was performed. Anidulafungin was used at conventional doses. Blood and PF samples were obtained on day 2 of treatment or on any of the following days. Results: A total of 31 patients in a serious clinical condition, as demonstrated by high mean clinical severity scale scores (APACHE II and SOFA scores), were included in the study. The mean area under the curve (AUC) in PF was 30% (31 19%) of that determined in the plasma and the maximum concentration (Cmax) reached in PF (mg/l) was close to 1 (0.9 0.5). No adverse effects were observed in any of the 31 patients. Conclusions: Anidulafungin at conventional doses reaches PF concentrations that exceed the minimum inhibitory concentration of the usual Candida spp, which explains the proven efficacy of this echinocandin in the treatment of Candida peritonitis in critically ill patients. | es_ES |
dc.description.sponsorship | This study was partially supported by a grant from Pfizer Spain (Avda Europa, 20-B, La Moraleja Business Park, 28108 Alcobendas, Madrid, Spain). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier BV | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Anidulafungin | es_ES |
dc.subject | Pharmacokinetics | es_ES |
dc.subject | Peritoneal fluid | es_ES |
dc.subject | Candida peritonitis | es_ES |
dc.subject | Critically ill patients | es_ES |
dc.title | Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/). | es_ES |
dc.identifier.doi | 10.1016/j.ijid.2019.07.008 | - |
dadun.citation.endingPage | 146 | es_ES |
dadun.citation.publicationName | International Journal of Infectious Diseases | es_ES |
dadun.citation.startingPage | 142 | es_ES |
dadun.citation.volume | 86 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.